We are proud to announce that Dr. Anil Bidkar’s presentation on a novel combinatorial therapeutic strategy, a CD46-targeted antibody-drug conjugate combined with a radioimmunotherapy agent for prostate cancer, was featured in the UroToday SNMMI 2025 conference highlights. This recognition underscores the significance of his innovative work in advancing targeted molecular therapies for prostate cancer.